Abstract
Short-Term and Long-Term Efficacy and Safety of Pemetrexed and Tislelizumab in Advanced Epidermal Growth Factor Receptor Tumor Protein 53 Co-Variant Lung Adenocarcinoma
Department of Thoracic Surgery, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, Haikou, Hainan 570208, 1Department of Thoracic Surgery, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, Hainan 570311, China
Correspondence Address:
Minbiao Chen, Department of Thoracic Surgery, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, Hainan 570311, China, E-mail: Chenminbiaogod@126.com
We attempt to study the short-term and long-term efficacy and safety of pemetrexed combined with tislelizumab in advanced epidermal growth factor receptor tumor protein 53 co-variant lung adenocarcinoma. The purpose is to explore the application effect of chemotherapy combined with immunotherapy in advanced epidermal growth factor receptor tumor protein 53 co-variant lung adenocarcinoma and provides reference for clinical work. We randomly selected 66 patients with advanced epidermal growth factor receptor+tumor protein 53 co-variant lung adenocarcinoma received from July 2019 to June 2021, then divided them into control group (n=33) and observation group (n=33). Treated control group with chemotherapy alone (pemetrexed), treated observation group chemotherapy combined with immunotherapy (pemetrexed+tislelizumab). Evaluated the short-term and long-term efficacy and safety of both groups, and checked the changes of immune indexes before and after treatment in both groups. In the comparison of short-term efficacy, observation group had higher disease control rate and objective remission rate than control group (p<0.05); but in the comparison of long-term efficacy, observation group had remarkably higher median disease progression-free survival than control group (p<0.05); both groups had no obvious difference in adverse reactions rate (p>0.05); in the comparison of immune indicators, observation group had higher cluster of differentiation 3+, cluster of differentiation 4+, cluster of differentiation 4+/cluster of differentiation 8+ and natural killer cells activities in T cell subsets than control group, but lower cluster of differentiation 8+ in T cell subgroup than control group (p<0.05). Chemotherapy combined with immunotherapy (pemetrexe+tislelizumab) application is effective and safe in advanced epidermal growth factor receptor+tumor protein 53 co-variant lung adenocarcinoma treatment, can prolong the survival period of patients, has good safety and will not have a great impact on immune indicators level.
